Use of cardiovascular drugs and risk of incident heart failure in patients with atrial fibrillation.
atrial fibrillation
congestive heart failure
drug treatment
gender
Journal
Journal of clinical hypertension (Greenwich, Conn.)
ISSN: 1751-7176
Titre abrégé: J Clin Hypertens (Greenwich)
Pays: United States
ID NLM: 100888554
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
24
03
2020
revised:
15
05
2020
accepted:
25
05
2020
pubmed:
16
7
2020
medline:
26
5
2021
entrez:
16
7
2020
Statut:
ppublish
Résumé
Congestive heart failure (CHF) is the most important cause of death in patients with atrial fibrillation (AF). We aimed to study the association between cardiovascular drugs in AF patients and incident CHF. The study population included all adults (n = 120 756) aged ≥45 years diagnosed with AF in Sweden diagnosed for the period 1998-2006. Outcome was incident congestive heart failure (follow-up 2007-2015) in AF patients. Associations between treatment with cardiovascular pharmacotherapies and CHF were evaluated using Cox regression to estimate hazard ratios (HRs) with 95% CIs, after adjustment for age, sociodemographic variables, and comorbidities. During a mean 5.3 years (SD 3.0) of follow-up, there were 28 257 (23.4%) incident cases of CHF. Treatment with beta-1-selective and non-selective beta-blockers and statins was associated with lower risks of incident CHF in men, HR, (95% CI); 0.90, (0.87-0.94); 0.90, (0.84-0.97), and 0.94, (0.90-0.99), respectively. Only beta-1-selective beta-blockers were protective in women 0.94 (0.91-0.98). Treatment with loop diuretics, potassium-saving agents, ACE inhibitors, and angiotensin receptor blockers was associated with a higher risk of CHF. For men, treatment with heart-active calcium channel blockers also led to a higher risk of CHF. In conclusion, we found that beta-blockers, in particular, but also statins were associated with lower risk of incident CHF in patients with AF.
Identifiants
pubmed: 32667702
doi: 10.1111/jch.13931
pmc: PMC8029913
doi:
Substances chimiques
Cardiovascular Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1396-1405Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Clin Cardiol. 2010 Jun;33(6):345-52
pubmed: 20556804
PLoS One. 2014 Aug 15;9(8):e104519
pubmed: 25126761
Drugs Aging. 2020 Feb;37(2):77-81
pubmed: 31797247
Lancet. 2017 Sep 16;390(10100):1211-1259
pubmed: 28919117
J Hypertens. 2009 Jun;27(6):1136-51
pubmed: 19451836
Int J Cardiol. 2013 Dec 10;170(2):208-14
pubmed: 24239153
Eur J Prev Cardiol. 2016 Mar;23(5):460-73
pubmed: 25701017
J Cardiol. 2018 Jul;72(1):26-32
pubmed: 29358024
J Clin Hypertens (Greenwich). 2011 Sep;13(9):639-43
pubmed: 21896142
BMC Public Health. 2013 Jul 18;13:670
pubmed: 23866784
Cardiol Rev. 2010 Jan-Feb;18(1):38-50
pubmed: 20010337
Eur J Clin Pharmacol. 2013 Feb;69(2):279-87
pubmed: 22990327
Basic Clin Pharmacol Toxicol. 2016 Nov;119(5):464-469
pubmed: 27112967
J Clin Hypertens (Greenwich). 2020 Aug;22(8):1396-1405
pubmed: 32667702
Ann Med. 2018 Mar;50(2):156-163
pubmed: 29172794
Clin Epidemiol. 2014 Jun 16;6:213-20
pubmed: 24966695
Nat Rev Cardiol. 2016 Mar;13(3):131-47
pubmed: 26658575
Pacing Clin Electrophysiol. 2016 Sep;39(9):907-13
pubmed: 27333877
J Intern Med. 2013 Nov;274(5):461-8
pubmed: 23879838
Circ Res. 2015 Mar 13;116(6):1058-73
pubmed: 25767290
Am J Cardiol. 2010 Jul 15;106(2):228-35
pubmed: 20599008
Eur J Heart Fail. 2005 Aug;7(5):787-91
pubmed: 15916919
Arch Intern Med. 2011 Mar 14;171(5):384-94
pubmed: 21059964
J Hypertens. 2018 Sep;36(9):1929-1935
pubmed: 29870433
J Epidemiol Community Health. 2004 Aug;58(8):635-41
pubmed: 15252064
Circulation. 2013 May 7;127(18):1916-26
pubmed: 23545139
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35
pubmed: 16897791
Heart Fail Rev. 2012 Mar;17(2):271-82
pubmed: 21748453